Pancreatic Cancer New Protocol: Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer Ulas D. Bayraktar, MD 2023-06-07
GastroEsophageal Cancer New Protocol: First-line regorafenib with nivolumab and chemotherapy in advanced esophageal, gastric, or gastro-esophageal junction cancer Ulas D. Bayraktar, MD 2023-06-07
Non-Small Cell Lung Cancer New Drug: Pralsetinib for non-small cell lung cancer with RET gene fusions Ulas D. Bayraktar, MD 2023-06-07
Multiple Myeloma New Drug: Talquetamab-tgvs for relapsed or refractory multiple myeloma Ulas D. Bayraktar, MD 2023-06-07
Prostate Cancer New Protocol: Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer Ulas D. Bayraktar, MD 2023-06-06
Biliary Tract Cancer New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer Ulas D. Bayraktar, MD 2023-05-20
Colorectal Cancer New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2023-05-20
Chronic Lymphocytic Leukemia New Reference: Ibrutinib and Rituximab for CLL Ulas D. Bayraktar, MD 2023-05-20
Follicular Lymphoma New Reference: SubQ Rituximab for Follicular Lymphoma Ulas D. Bayraktar, MD 2023-05-20
Breast Cancer New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer Ulas D. Bayraktar, MD 2023-05-20
